Skip to search formSkip to main contentSkip to account menu

R 125489

Known as: R-125489, R125489 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2011
Highly Cited
2010
Highly Cited
2010
Background Antiviral drugs are an important option for managing infections caused by influenza viruses. This study assessed the… 
Highly Cited
2010
Highly Cited
2010
ABSTRACT Two neuraminidase (NA) inhibitors, zanamivir (Relenza) and oseltamivir phosphate (Tamiflu), have been licensed for use… 
Review
2010
Review
2010
  • M. Yamashita
  • Antiviral chemistry & chemotherapy
  • 2010
  • Corpus ID: 6155646
Oseltamivir and zanamivir are currently licensed worldwide for influenza treatment and chemoprophylaxis. Both drugs require twice… 
Highly Cited
2010
Highly Cited
2010
ABSTRACT The neuraminidase inhibitors (NAIs) zanamivir and oseltamivir are currently the only antiviral drugs effective for the… 
Highly Cited
2010
Highly Cited
2010
Currently, two neuraminidase (NA) inhibitors, oseltamivir and zanamivir, which must be administrated twice daily for 5 days for… 
2010
2010
CS-8958, a prodrug of laninamivir (R-125489), is currently under development as an inhaled anti-influenza drug. In this study… 
Highly Cited
2009
Highly Cited
2009
ABSTRACT CS-8958 is a prodrug of the pharmacologically active form R-125489, a selective neuraminidase inhibitor, and has long… 
Highly Cited
2008
Highly Cited
2008
ABSTRACT Two neuraminidase (NA) inhibitors, zanamivir (Relenza) and oseltamivir phosphate (Tamiflu), have been licensed for the…